Normative Instruction

Published on 01/03/2026 14:14Modified on 27/07/2026 19:22
Share:

2026

Normative Instruction

Subject

NORMATIVE INSTRUCTION No. 448 OF 1 JUNE 2026

Amends Normative Instruction IN no. 389 of 29 July 2025, which provides for the temporary health measures to be adopted by ports and airports considering the current epidemiological scenario, pursuant to Articles 12 and 19 of Collegiate Board Resolution – RDC No. 932/2024.

2025

Normative Instruction

Subject

NORMATIVE INSTRUCTION No. 394 OF 15 AUGUST 2025

Provides for general requirements, analytical tolerances, label flow, list of categories, and proof of expiration date for sanitizing products, in accordance with Collegiate Board Resolution No. 989 of 15 August 2025.

NORMATIVE INSTRUCTION – IN No. 360 OF 23 APRIL 2025

It defines the list of isolated or combined substances used in prescription and prescription-retaining medicinal products, as provided for in Collegiate Board Resolution – RDC No. 471 of 23 February 2021.

2024

Normative Instruction

Subject

NORMATIVE INSTRUCTION – IN NO. 338 OF 29 NOVEMBER 2024

Establishes, in accordance with Anvisa Collegiate Board Resolution RDC no. 945 of 29 November 2024, the list of Equivalent Foreign Regulatory Authorities (EFRAs) and details the criteria to adopt the optimized analysis procedure through regulatory reliance, as well as through risk and complexity assessment of applications for DDCM, DEEC, substantial alterations in the investigational product, and substantial amendments to the clinical protocol.

ANVISA NORMATIVE INSTRUCTION – IN No. 301 OF 17 MAY 2024

Establishes the list of medicinal gases classified as medicines subject to notification.

NORMATIVE INSTRUCTION – IN NO. 292 OF 2 MAY 2024

Provides for the specific criteria and procedures to define the Equivalent Foreign Regulatory Authorities for the process of health inspection of manufacturers of active pharmaceutical ingredients, Cannabis products for medicinal purposes, medicinal products, and biological products, as well as the optimized analysis procedure for the purposes of Good Manufacturing Practices Certification.

Normative Instruction – IN no. 290 of 4 April 2024

Establishes, in the terms of Collegiate Board Resolution – RDC no. 741 of 10 August 2022, optimized procedures for the purposes of analysis and decisionmaking regarding petitions for marketing authorization for medical devices, by taking advantage of analyses carried out by an Equivalent Foreign Regulatory Authority (EFRA).

NORMATIVE INSTRUCTION – IN No. 289 OF 20 MARCH 2024

Establishes, in accordance with Collegiate Board Resolution – RDC No. 741 of 10 August 2022, the criteria applied to the optimized analysis procedure that uses assessments conducted by an Equivalent Foreign Regulatory Authority (EFRA) for the analysis of marketing authorization and post-marketing authorization petitions for medicinal products, biological products, vaccines, and letters of adequacy of active pharmaceutical ingredient dossiers (CADIFA) in Brazilian territory.

NORMATIVE INSTRUCTION – IN No. 281 OF 22 FEBRUARY 2024

It establishes the way to regularize the different categories of food and packaging, and the respec􀆟ve documenta􀆟on that must be presented.

2022

Normative Instruction

Subject

NORMATIVE INSTRUCTION – IN No. 199 OF 12 DECEMBER 2022

Establishes the list of active pharmaceutical ingredients with phonetic or graphic similarity with other ingredients.

NORMATIVE INSTRUCTION – IN No. 198 OF 12 DECEMBER 2022

Establishes specific requirements for the labelling of large volume parenteral solutions, solutions for irrigation, dialysis, plasma expanders, and small-volume parenteral solutions.

NORMATIVE INSTRUCTION – IN No. 183 OF 5 SEPTEMBER 2022

Establishes the list of oral medicines intended for local ac􀆟on in the gastrointes􀆟nal tract that are candidates for biowaiver, as provided for in Ar􀆟cle 7, Item VI, of Collegiate Board Resolu􀆟on – RDC No. 749 of 5 September 2022.

NORMATIVE INSTRUCTION – IN No. 182 OF 5 SEPTEMBER 2022

Provides for permeability tests with Caco-2 cells and the valida􀆟on of such assays.

NORMATIVE INSTRUCTION (IN) No. 139 OF 30 MARCH 2022

Provides for the Good Manufacturing Practices complementary to the reference and retention samples.

NORMATIVE INSTRUCTION (IN) No. 134 OF 30 MARCH 2022

Provides for the Good Manufacturing Practices complementary to computerized systems used in the manufacture of medicinal products.

NORMATIVE INSTRUCTION (IN) No. 132 OF 30 MARCH 2022

Provides for the Good Manufacturing Practices complementary to Liquid Medicines, Creams, or Ointments.

NORMATIVE INSTRUCTION (IN) No. 131 OF 30 MARCH 2022

Provides for the Good Manufacturing Practices complementary to sampling activities of raw materials and packaging materials used in the manufacture of medicinal products.

NORMATIVE INSTRUCTION (IN) NO. 127 OF 30 MARCH 2022

Provides for the Good Manufacturing Practices complementary to Biological Inputs and Medicinal Products.

2021

Normative Instruction

Subject

NORMATIVE INSTRUCTION – IN NO. 88 OF 26 MARCH 2021

Establishes the maximum tolerated limits (MTLs) of contaminants in foods.

NORMATIVE INSTRUCTION- IN NO. 87 OF 15 MARCH 2021

Establishes the list of authorized vegetal species, designations, composition of fatty acids, the maximum acidity values, and the maximum peroxide index values for vegetal oils and fats.

2020

Normative Instruction

Subject

NORMATIVE INSTRUCTION – IN NO. 75 OF 8 OCTOBER 2020

Establishes the technical requirements for declaring the nutrition labeling of packaged foods.

NORMATIVE INSTRUCTION - IN NO. 67 OF 1 SEPTEMBER 2020

Provides for the inclusion of new formula declaration on the label of foods when their composition is altered.

2019

Normative Instruction

Subject

NORMATIVE INSTRUCTION NO. 51 OF 19 DECEMBER 2019

Establishes the list of maximum residue limits (MRL), acceptable daily intake (ADI), and acute reference dose (ARfD) for active pharmaceutical ingredients (API) of veterinary medicinal products in foods of animal origin.

Share: